Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) is a family of transcription factors that regulate inflammation, immune responses, cell survival, and proliferation. NF-kB is a convergence point where metal toxicity, pathogen signaling, and chronic disease intersect — activated by heavy metals, LPS, cytokines, and oxidative stress through overlapping upstream pathways.
Core Pathway
Canonical Activation
- In resting cells, NF-kB dimers (typically p65/p50) are held inactive in the cytoplasm by IkB inhibitory proteins.
- Activation signals (TNF-alpha, IL-1, LPS, metals, ROS) activate the IKK complex (IKKalpha/IKKbeta/NEMO), which phosphorylates IkB, targeting it for proteasomal degradation.
- Released NF-kB translocates to the nucleus and drives transcription of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta), anti-apoptotic genes (Bcl-2, Bcl-xL), and adhesion molecules.
Downstream Effects
- Inflammation: IL-6, TNF-alpha, IL-1beta, COX-2, iNOS.
- Cell survival: anti-apoptotic proteins that protect cells from programmed death.
- Immune activation: MHC molecules, immunoglobulin light chains, cytokine receptors.
- Tissue remodeling: matrix metalloproteinases matrix metalloproteases.
Metal Activation of NF-kB
Nickel
- nickel activates NF-kB through ROS generation, contributing to both its carcinogenic and inflammatory effects [1].
- In endometriosis, dietary nickel exposure may drive NF-kB-mediated inflammation, contributing to the gastrointestinal and gynecological symptoms seen in Ni ACM [2].
- NF-kB activation by nickel is part of its role as a metalloestrogen and inflammatory driver.
Arsenic -- The Dose Paradox
- Low-dose arsenic activates NF-kB, promoting cell survival and proliferation — this may be key to arsenic's tumor promotion activity [1].
- High-dose arsenic inhibits NF-kB, inducing apoptosis — this is exploited therapeutically in acute promyelocytic leukemia (APL) treatment with arsenic trioxide.
- This biphasic response means arsenic can be both a carcinogen (low dose, chronic) and a cancer treatment (high dose, acute).
Cadmium
- Activates NF-kB via ROS-dependent mechanisms, driving inflammatory cytokine production in kidney, liver, and gut tissues [3].
- NF-kB activation contributes to cadmium-induced renal inflammation and progressive nephron loss.
Lead
- Activates NF-kB in the CNS, contributing to neuroinflammation. LPS from Pb-induced gut dysbiosis further amplifies NF-kB signaling via TLR4 in microglia [4].
Mercury
- Hg compounds activate NF-kB through thiol oxidation and ROS generation, driving autoimmune and inflammatory responses.
NF-kB in Disease Contexts
Neurodegeneration
- NF-kB-driven neuroinflammation is a shared pathway across AD and PD, amplified by metal-induced microglial activation and gut-derived LPS [4].
Autoimmune Disease
- NF-kB activation by environmental metals contributes to autoimmune thyroid disease, rheumatoid arthritis, and IBD [5], [6]].
Endometriosis
- H2S and nickel both activate NF-kB in endometriotic tissue, driving inflammatory cytokine production, angiogenesis, and lesion growth. This links dietary nickel exposure to disease progression.
Cancer
- NF-kB activation promotes tumor cell survival, proliferation, and resistance to apoptosis. Metal-induced constitutive NF-kB activation is a proposed mechanism in metal carcinogenesis.
Therapeutic Implications
NF-kB inhibition is a therapeutic target across multiple metal-associated diseases. Anti-inflammatory dietary patterns (e.g., mediterranean diet) may partially exert their effects through NF-kB suppression. However, complete NF-kB blockade compromises immune defense, creating a therapeutic window challenge.
Key Sources
Connections
- nickel, arsenic, cadmium, lead, mercury — all activate NF-kB
- inflammation — NF-kB is the master inflammatory transcription factor
- oxidative stress — ROS activates NF-kB; NF-kB target genes produce more ROS
- metal carcinogenesis — NF-kB-mediated cell survival promotes tumorigenesis
- gut metal microbiome — LPS from metal-induced dysbiosis activates NF-kB via TLR4